PURPOSE: The Veterans Affairs (VA) healthcare system treats approximately 3% of patients with cancer in the United States each year. We measured the quality of nonmetastatic colorectal cancer (CRC) care in VA as indicated by concordance with National Comprehensive Cancer Network practice guidelines (six indicators) and timeliness of care (three indicators). PATIENTS AND METHODS: A retrospective medical record abstraction was done for 2,492 patients with incident stages I to III CRC diagnosed between October 1, 2003, and March 31, 2006, who underwent definitive CRC surgery. Patients were treated at one or more of 128 VA medical centers. The proportion of patients receiving guideline-concordant care and time intervals between care processes were calculated. RESULTS: More than 80% of patients had preoperative carcinoembryonic antigen determination (ie, stages II to III disease) and documented clear surgical margins (ie, stages II to III disease). Between 72% and 80% of patients had appropriate referral to a medical oncologist (ie, stages II to III disease), preoperative computed tomography scan of the abdomen and pelvis (ie, stages II to III disease), and adjuvant fluorouracil-based chemotherapy (ie, stage III disease). Less than half of patients with stages I to III CRC (43.5%) had a follow-up colonoscopy 7 to 18 months after surgery. The mean number of days between major treatment events included the following: 26.6 days (standard deviation [SD], 38.2; median, 20 days) between diagnosis and initiation of treatment (in stages II to III disease); 64.8 [corrected] days (SD, 54.9; median, 50 days) between definitive surgery and start of adjuvant chemotherapy (in stages II to III disease); and 444.2 [corrected] days (SD, 182.1; median, 393 days) between definitive surgery and follow-up colonoscopies (in stages I to III disease). CONCLUSION: Although there is opportunity for improvement in the area of cancer surveillance, the VA performs well in meeting established guidelines for diagnosis and treatment of CRC.
PURPOSE: The Veterans Affairs (VA) healthcare system treats approximately 3% of patients with cancer in the United States each year. We measured the quality of nonmetastatic colorectal cancer (CRC) care in VA as indicated by concordance with National Comprehensive Cancer Network practice guidelines (six indicators) and timeliness of care (three indicators). PATIENTS AND METHODS: A retrospective medical record abstraction was done for 2,492 patients with incident stages I to III CRC diagnosed between October 1, 2003, and March 31, 2006, who underwent definitive CRC surgery. Patients were treated at one or more of 128 VA medical centers. The proportion of patients receiving guideline-concordant care and time intervals between care processes were calculated. RESULTS: More than 80% of patients had preoperative carcinoembryonic antigen determination (ie, stages II to III disease) and documented clear surgical margins (ie, stages II to III disease). Between 72% and 80% of patients had appropriate referral to a medical oncologist (ie, stages II to III disease), preoperative computed tomography scan of the abdomen and pelvis (ie, stages II to III disease), and adjuvant fluorouracil-based chemotherapy (ie, stage III disease). Less than half of patients with stages I to III CRC (43.5%) had a follow-up colonoscopy 7 to 18 months after surgery. The mean number of days between major treatment events included the following: 26.6 days (standard deviation [SD], 38.2; median, 20 days) between diagnosis and initiation of treatment (in stages II to III disease); 64.8 [corrected] days (SD, 54.9; median, 50 days) between definitive surgery and start of adjuvant chemotherapy (in stages II to III disease); and 444.2 [corrected] days (SD, 182.1; median, 393 days) between definitive surgery and follow-up colonoscopies (in stages I to III disease). CONCLUSION: Although there is opportunity for improvement in the area of cancer surveillance, the VA performs well in meeting established guidelines for diagnosis and treatment of CRC.
Authors: Denise M Hynes; Ruth A Perrin; Steven Rappaport; Joanne M Stevens; John G Demakis Journal: J Am Med Inform Assoc Date: 2004-06-07 Impact factor: 4.497
Authors: Joseph L Goulet; Joseph Erdos; Sue Kancir; Forrest L Levin; Steven M Wright; Stanlie M Daniels; Lynnette Nilan; Amy C Justice Journal: Med Care Date: 2007-01 Impact factor: 2.983
Authors: Paul B Jacobsen; David Shibata; Erin M Siegel; Mihaela Druta; Ji-Hyun Lee; Jan Marshburn; Linda Davenport; Hugh Cruse; Richard Levine; Avantica Gondi; Richard Brown; Mokenge Malafa Journal: J Oncol Pract Date: 2007-03 Impact factor: 3.840
Authors: Christopher E Desch; Al B Benson; Mark R Somerfield; Patrick J Flynn; Carol Krause; Charles L Loprinzi; Bruce D Minsky; David G Pfister; Katherine S Virgo; Nicholas J Petrelli Journal: J Clin Oncol Date: 2005-10-31 Impact factor: 44.544
Authors: Erin J Aiello Bowles; Leah Tuzzio; Cheryl J Wiese; Beth Kirlin; Sarah M Greene; Steven B Clauser; Edward H Wagner Journal: Cancer Date: 2008-02-15 Impact factor: 6.860
Authors: Leah L Zullig; George L Jackson; Raye Anne Dorn; Dawn T Provenzale; Rebecca McNeil; Catherine M Thomas; Michael J Kelley Journal: Mil Med Date: 2012-06 Impact factor: 1.437
Authors: Aaron P Thrift; Jennifer R Kramer; Christine M Hartman; Kathryn Royse; Peter Richardson; Yongquan Dong; Suchismita Raychaudhury; Roxanne Desiderio; Dina Sanchez; Sharmila Anandasabapathy; Donna L White; Elizabeth Y Chiao Journal: J Acquir Immune Defic Syndr Date: 2019-07-01 Impact factor: 3.731
Authors: R Ryanne Wu; Linda S Kinsinger; Dawn Provenzale; Heather A King; Patricia Akerly; Lottie K Barnes; Santanu K Datta; Janet M Grubber; Nicholas Katich; Rebecca B McNeil; Robert Monte; Nina R Sperber; David Atkins; George L Jackson Journal: J Gen Intern Med Date: 2014-12 Impact factor: 5.128
Authors: George L Jackson; Leah L Zullig; Sean M Phelan; Dawn Provenzale; Joan M Griffin; Steven B Clauser; David A Haggstrom; Rahul M Jindal; Michelle van Ryn Journal: Cancer Date: 2015-03-17 Impact factor: 6.860
Authors: George L Jackson; Leah L Zullig; S Yousuf Zafar; Adam A Powell; Diana L Ordin; Ziad F Gellad; David Abbott; James M Schlosser; Janis Hersh; Dawn Provenzale Journal: J Natl Compr Canc Netw Date: 2013-04-01 Impact factor: 11.908
Authors: Melissa Y Carpentier; Jasmin A Tiro; Lara S Savas; L Kay Bartholomew; Trisha V Melhado; Sharon P Coan; Keith E Argenbright; Sally W Vernon Journal: J Cancer Surviv Date: 2012-12-18 Impact factor: 4.442
Authors: Melissa Y Carpentier; Sally W Vernon; L Kay Bartholomew; Caitlin C Murphy; Shirley M Bluethmann Journal: J Cancer Surviv Date: 2013-05-16 Impact factor: 4.442